Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ: INCY )

58.97 +0.97 (+1.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Expert Ratings For Incyte
Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ: 
Via Benzinga
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
From Incyte
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Incyte Names New Member to Its Board of Directors
From Incyte
Via Business Wire
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license... 
Via Benzinga
Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America
Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer
Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as... 
Via Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
10 Biggest Price Target Changes For Thursday
Deutsche Bank reduced the price target for FedEx Corporation (NYSE: 
Via Benzinga
Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD
The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for... 
Via Benzinga
Exposures Product Safety
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
From Incyte
Via Business Wire
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
Find out what held these laggards back. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis
The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate... 
Via Benzinga
Exposures Product Safety
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
From Incyte
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada
Health Canada has given conditional approval to Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma. Cholangiocarcinoma... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
Price Over Earnings Overview: Incyte
In the current market session, Incyte Inc. (NASDAQ:INCY) is trading at $72.46, after a 0.1% gain. However, over the past month, the stock fell by 4.23%, and in the... 
Via Benzinga
Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
From Incyte
Via Business Wire
FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know
The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR... 
Via Benzinga
Exposures Product Safety
AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly
AbbVie stock collapsed Wednesday after the FDA said it would have to add a warning to the label for arthritis drug Rinvoq. 
Via Investor's Business Daily
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval
The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (... 
Via Benzinga
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
For Hedge Funds, This Is The Worst 6 Months Since The Financial Crisis: Here's Why
The most popular hedge fund positions have fared exceptionally poorly in recent months. The core issues behind recent (and continuing) hedge fund underperformance: concentration, crowding and... 
Via Talk Markets
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.